Corneal Crosslinking for Treatment of Corneal Neovascularization

Recruiting now · Phase 2/Phase 3

Conditions studied: Corneal Neovascularization

In brief

The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.

Key facts

Study ID

NCT04787471

Run by

Price Vision Group

People needed

62

Starts

2021-05-03

Expected to finish

2026-09-15

Last updated by the study team

2025-07-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids.
• Signed written informed consent.

You may not qualify if…

• Known sensitivity to treatment medications
• Current condition that in the investigator's opinion could compromise safety or data integrity.
• Pregnancy (including plan to become pregnant) or lactation during the course of the study

Where it is running

• Price Vision Group — Indianapolis, Indiana, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.